UNSPSC 51101662: Halofuginone

This classification denotes an angiogenesis activator inhibitor and alkaloid with the molecular formula C16H17BrClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L31MM1385E, chemically known as 4(3h)-quinazolinone, 7-bromo-6-chloro-3-(3-(3-hydroxy-2-piperidinyl)-2-oxopropyl)-, trans- but generally known as halofuginone, which bears US NIH Compound Identifier 62891. European Medicines Agency schedules Halofuginone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08000MIG.

UNSPSC 51101662 Halofuginone, a Commodity code, does not align with recent state and local procurement activity. The code nominally addresses a specific veterinary pharmaceutical active ingredient, yet the recent opportunities posted under this code solicitation involve naloxone (an opioid antagonist), generic multi-source pharmaceuticals and over-the-counter products, medical and first aid supplies for fire-rescue operations, and direct-to-manufacturer prescription programs — none of which are halofuginone or closely related to it. The mismatch suggests either miscoding in the procurement system or that the code is used as a catch-all for pharmaceutical and health-supply procurement without regard to the specific substance named.

The four recent opportunities posted under this code span multiple issuing-body types: Seminole County, Florida (health department procurement); Texas Health and Human Services Commission (state agency RFI); City of Tampa Fire Department (municipal rescue-division supplies); and the Minnesota Multistate Cooperative Purchasing Alliance (multi-state cooperative vehicle). Geographic activity centers on Florida, Texas, and Minnesota, with Oregon also participating in the MMCAP cooperative. The Seminole County IFB (due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually; the Texas HHS Commission RFI (response due April 3, 2026) explored direct-to-manufacturer prescription contracting; the City of Tampa IFB (due March 13, 2026) requested medical and first aid supplies for fire rescue, estimated at $700,000, with a certified Small Local Business Enterprise set-aside and 5 percent bid discount; and the MMCAP RFP (due March 26, 2026) sought generic pharmaceuticals and OTC products through authorized wholesalers for state and local facilities. The systematic divergence between the code's nominal scope and the actual work being procured indicates this code may not be reliable for targeting pharmaceutical or health-supply opportunities.